An appraisal of a 17-year primary thyroid stimulating hormone (TSH) screening programme for the detection of congenital hypothyroidism was carried out to establish the reference interval of cord blood TSH in unaffected infants; the mean cord blood TSH concentration of affected infants and the incidence of congenital hypothyroidism in the Najran province of Saudi Arabia. Our findings show a reference interval of cord blood TSH of 2.0-16.8 mU/l in unaffected infants; a mean cord blood TSH concentration of 399 mU/l in affected infants; a false positive rate for the diagnosis of at-risk infants of 1.02% and a congenital hypothyroidism incidence rate of 34/100 000 (1 : 2931) live births. These findings suggest that there is a need to reset the cord blood TSH concentration for the detection of at-risk infants. We suggest that the detection level of cord blood TSH for the recognition of at-risk infants can be set at 90 mU/l rather than the recommended level of 30 mU/l. This should reduce the false positive rate for detection of infants at risk of congenital hypothyroidism.
Introduction
The Saudi Arabian screening programme for the detection of congenital hypothyroidism is a primary thyroid stimulating hormone (TSH) screening of cord blood obtained at delivery. Estimation of the infant's venous blood thyroxine (T4) is used for confirmation of suspiciously high cord blood TSH level. The recommended detection level of cord blood TSH for identifying at-risk infants is 30 mU/l, while neonatal venous blood total T4 lower than 60 nmol/l or free T4 lower than 12 pmol/l is required for confirmation of congenital hypothyroidism. The Najran province of Saudi Arabia joined the national screening programme in 1990 with the Laboratory Department of King Khalid Hospital, and later the Laboratory Department of Najran General Hospital serving as the screening laboratories for infants delivered within the province. Experience gathered over a period of 17 years (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) of the on-going programme suggests that the recommended cord blood TSH level for detection of congenital hypothyroidism is too low leading to a high false positive rate for the recognition of at-risk infants. There may therefore be a need to redefine the detection level of cord blood TSH to reduce the false positive rate for identifying infants at the risk of congenital hypothyroidism in the local population. We set out to determine the reference interval of cord blood TSH of unaffected neonates and to compare this with the distribution and population mean value of cord blood TSH of affected infants to assess the efficiency of detection of at-risk infants using the recommended detection value of cord blood TSH. We also determine the incidence of congenital hypothyroidism, diagnosed by laboratory screening and confirmed clinically, in the local population using the entire population of neonates screened over the study period.
Materials and Methods

Materials
The materials used for this study were Delfia FluoroImmuno-Assay System (Wallac Oy, Turku, Finland); Delfia hTSH (human TSH) and Delfia T4 and FT4 (thyroxine) assay kits (Wallac Oy, Turku, Finland). Quality control sera (Kodak Clinical Diagnostics Ltd., Amersham, UK), cord blood from each neonate and venous blood from neonates when necessary were also used.
Methods
Blood samples were obtained from the maternity units of King Khalid Hospital and Najran General Hospital in Najran province of Saudi Arabia. At the time of delivery, 5 ml of cord blood was collected into a plain sample bottle from the placental side of the cord before delivering the placenta. Serum was separated from the clotted blood by centrifugation and was immediately refrigerated until analysed. All samples were analysed within 3 days of sample collection. All assays were carried out on the Delfia Fluoro-Immuno Assay system according to the reagent kit manufacturer's instructions. Three hormonal levels (low, medium and high) of commercial quality control sera (Kodak Clinical Diagnostics Ltd., Amersham, UK) were analysed with each batch of samples. As required by the national screening protocol, all cord blood samples with TSH values 30 mU/l and above were assayed for their T4 levels. In the first 5 years of the screening programme, total T4 was used for the confirmation of congenital hypothyroidism while free T4 (FT4) was used subsequently. If the value of total T4 or FT4 was lower than 60 nmol/l or 12 pmol/l, respectively, a venous blood sample was taken from the affected infant for repeat TSH and T4/FT4 analyses to confirm congenital hypothyroidism. All cases identified by hormonal measurements were confirmed by clinical assessment as reported earlier by Al-Jurayyan, et al. [1] . The performance characteristics of the assays were determined using the results of quality control sera obtained during routine analyses. The reference interval for cord blood TSH was determined from the results of cord blood samples obtained from babies delivered in a month randomly selected during the first 4 years of the screening programme. For each year of the study, incidence rates of confirmed congenital hypothyroidism and false positive high cord blood TSH levels were determined. The false positives were infants whose TSH levels were 30 mU/l and above but whose T4 levels were normal and were clinically euthyroid. The incidence of congenital hypothyroidism for the population studied was determined using figures generated from the entire population of neonates screened. The cord blood TSH values of all confirmed cases of congenital hypothyroidism were pooled with the values of the sample of unaffected infants used for the determination of the reference interval to generate a Receiver-Operating Characteristic (ROC) curve using the MedCalc statistical software. The ROC curve was used to determine the appropriate detection level of cord blood TSH for the diagnosis of congenital hypothyroidism.
Results
The intra-batch and inter-batch analytical imprecision for TSH assay were 5.8% and 8.8%, respectively, while the assay detection limit was 0.1 mU/l. The T4 and FT4 assays had detection limits of 2 nmol/l and 1 pmol/l, respectively.
Seven hundred and twenty neonatal samples were analysed during the month that was randomly selected for the determination of cord blood TSH reference interval. Five samples which yielded TSH values greater than 30 mU/l were treated as outliers and excluded from the determination of TSH reference interval. Figure 1 shows the frequency distribution of cord blood TSH values used for the reference interval determination. The frequency distribution curve being non-Gaussian, the reference interval for cord blood TSH was defined by the 2.5-97.5th percentile of the study population as recommended by the International Federation of Clinical Chemistry (IFCC) [2] . The reference interval obtained from this population was 2.0-16.8 mU/l. Figure 2 shows the frequency distribution of cord blood TSH values of the neonates confirmed positive for congenital hypothyroidism. The range of cord blood TSH for the confirmed cases was 117-777 mU/l with a mean of 399 mU/l and 95% confidence interval of 352-445 mU/l. Figure 3 is the ROC curve of pooled data of cord blood of unaffected and affected infants. ROC curve analysis shows that a cord blood TSH of 93 mU/l separates unaffected infants from congenital hypothyroidism infants with a sensitivity of 98.8% and a specificity of 100%. The ranges of venous blood T4 and FT4 of confirmed positive cases were 2.0-59.6 nmol/l and 1.1-9.0 pmol/l, respectively. Table 1 shows the annual breakdown of the number of neonates screened and the incidence of true positive and false positive high cord blood TSH values.
Discussion
The detection level of diagnostic tests for clinical conditions that are amenable to interventional management are usually set to increase the sensitivity of the test to detect true positives for the condition while minimizing the number of false negatives. The detection levels of diagnostic tests for identifying affected population for a clinical condition are best determined by the analysis of ROC curves of values of the diagnostic test generated from populations of affected and unaffected individuals [3] . Studies of incidence of congenital hypothyroidism based on laboratory indices have reported the adoption of different detection levels of blood TSH for the recognition of the at-risk infant [4] [5] [6] . These detection levels have been related to values in unaffected infants, but it is unclear how they were determined. We suggest that the detection level for identifying the at-risk infant should be related to blood TSH values of unaffected as well as confirmed affected infants.
Using the recommended cord blood TSH value of 30 mU/l for the recognition of neonates at risk of congenital hypothyroidism, our study identified 1512 at-risk infants from a total population of 143 623 infants screened. Only 49 of the infants identified as being at risk were confirmed with subnormal blood T4 levels and clinical assessment as being hypothyroid. This gives a population incidence of 34/100 000 or 1 : 2931 live births and a false positive diagnosis rate of 1.02% which is much higher than rates of 0.05-0.3% reported from other primary TSH screening programmes [7, 8] . Our results show that the lowest level of cord blood TSH, in confirmed cases of congenital hypothyroidism, was 117 mU/l. This is consistent with the results from a Swedish study [9] in which TSH of blood samples collected from confirmed cases of congenital hypothyroidism, which had been stored for 5 years and reanalysed, showed levels above 100 mU/l. The ROC curve shows that if the detection limit of cord blood TSH had been set at 90 mU/l in our study, no case of congenital hypothyroidism would have been missed. This would have improved the efficiency of the screening programme and led to significant cost saving. This would also have reduced the emotional stress of mothers whose infants would have been inappropriately labelled as vulnerable. We would therefore recommend that the detection level of cord blood TSH for the recognition of at-risk neonates be raised to 90 mU/l. This should still provide adequate safeguard against missed true positive cases.
Our study has shown that the population incidence of congenital hypothyroidism in Najran province of Saudi Arabia is 1:2931 live births. This rate is comparable to the incidence reported from other programmes in Saudi Arabia and elsewhere [10] [11] [12] [13] [14] . Our finding, which covers a 17-year study period, shows a lower incidence of congenital hypothyroidism than the 1:1400 reported for the first 5-year period of the screening programme when only 30 810 infants had been screened from the same province of Saudi Arabia by Al-Jurayyan, et al. [1] . We believe that the apparently higher rate reported by these investigators was a fortuitously high incidence in the first few years of the programme rather than a regional peculiarity as suggested by them. Our findings support the wisdom of determination of population incidence of a clinical problem based on a large population of at-risk individuals or many years' observation as suggested by Al-Jurayyan, et al.
